CMS proposal could curb innovation in faster cancer drug delivery
A new CMS rule would price injectable cancer biologics the same as their IV originals, risking a slowdown in patient-friendly drug development.
The Centers for Medicare & Medicaid Services has issued a proposal that would classify injectable, subcutaneous forms of biologic cancer therapies under the same price-negotiation framework as their original intravenous counterparts. Developing a safe, minutes-long injection often involves years of research, clinical trials, and substantial investment, yet the CMS plan would apply the older drug’s negotiated price to the newer version.
Proponents of the change claim it protects the integrity of Medicare’s negotiation program, but patient advocates contend it overlooks the clinical and quality-of-life benefits of reduced infusion times. Studies show subcutaneous administration can cut infusion chair time by up to 97% and lower staff workload, while also delivering cost savings for Medicare. The proposal risks discouraging pharmaceutical innovation, potentially limiting future advances that make cancer treatment less burdensome, especially for patients in rural areas with limited oncology services.
Why it matters
The rule could slow development of quicker, less taxing cancer treatments, affecting patient quality of life and health-system costs.
In this story